CClinicalTrials.gg
Not yet recruitingNCT07787286Updated Aug 26, 2026

EMS vs. Resistance Training in Overweight Women

An interventional study of Resistance Training and Electrical Muscle Stimulation in Obesity & Overweight, sponsored by Birjand University of Medical Sciences. Not yet recruiting at 1 site in Iran. Open to female participants aged 35 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Birjand University of Medical Sciences · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
35 Years to 45 Years
Sex
Female
01

Study summary

This study aims to compare the effects of eight weeks of resistance training versus electrical muscle stimulation (EMS) on oxidative stress indicators and cellular health index in overweight and obese women aged 35-45 years. Forty-two participants will be randomly assigned to three groups: resistance training, EMS, and control. The resistance training group will perform progressive resistance exercises three times per week for eight weeks. The EMS group will receive electrical muscle stimulation on biceps, abdominal, back, and quadriceps muscles three times per week for eight weeks. The control group will receive no intervention. Oxidative stress markers including superoxide dismutase (SOD), glutathione peroxidase (GPX), catalase (CAT), glutathione, protein carbonyl (PC), and total antioxidant capacity (TAC) will be measured from blood samples. Cellular health will be assessed using phase angle (PhA) derived from bioelectrical impedance analysis. Upper and lower body muscular strength and endurance will also be evaluated. All measurements will be taken at baseline and 48 hours after the last training session. The primary outcome is change in phase angle. Secondary outcomes include changes in oxidative stress markers and physical performance.

Read the detailed description

This is a quasi-experimental, pretest-posttest, parallel-group clinical trial with three arms: resistance training, electrical muscle stimulation (EMS), and control. Forty-two overweight and obese women (BMI 25-35 kg/m², aged 35-45 years) will be randomly assigned to the three groups (n=14 each). Participants must meet the inclusion criteria including no history of cardiovascular disease, no pregnancy or lactation, no use of medications affecting muscle or fat mass, and no recent lower/upper extremity injuries.

Intervention details:

Resistance training group: 8 weeks, 3 sessions/week, 50 minutes each session. Exercises include upper body, back, abdominal, and lower body movements. Training intensity will progress from 60% of 1RM in week 1 to 85% of 1RM in week 8.

EMS group: 8 weeks, 3 sessions/week, 30 minutes each session. EMS will be applied to biceps brachii, abdominals, back, and quadriceps muscles using frequency of 35-70 Hz, pulse duration 100 μs, and pulse period 50 ms. Electrode size: 150 × 240 mm. Intensity will be progressively increased over the 8 weeks.

Control group: No exercise intervention during the study period.

Outcome measurements:

Primary outcome: Phase angle (PhA) measured using bioelectrical impedance analysis (Inbody770).

Secondary outcomes: Serum levels of SOD, GPX, CAT, glutathione, PC, and TAC measured using ELISA kits. Upper body strength (bench press) and lower body strength (squat) measured via 1RM testing. Upper body endurance (push-up test) and lower body endurance (bodyweight squat test) measured in 60-second tests.

Statistical analysis: Data will be analyzed using ANCOVA with pretest scores as covariates. Correlation between phase angle changes and oxidative stress markers will be assessed using Pearson's correlation coefficient. All analyses will be performed using SPSS, with significance set at p \< 0.05.

02

Conditions studied

  • Obesity & Overweight

Keywords

  • Obesity
  • Overweight
  • Resistance Training
  • Electric Stimulation Therapy
  • Oxidative Stress
  • Phase Angle
  • Superoxide Dismutase
  • Catalase
  • Body Composition
03

Who can participate

Ages eligible
35 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy non-menopausal women aged 35 to 45 years

Body mass index (BMI) between 25 and 35 kg/m²

Similar menstrual cycle pattern

No pregnancy or lactation

No continuous medication affecting fat or muscle mass (based on health and fitness questionnaire)

No history of cruciate ligament injury or other upper/lower extremity injuries in the past 6 months

No history of heart attack or acute cardiovascular disease

No use of medications (glucocorticoids, beta-blockers, alcohol) or antioxidant supplements that could interfere with study results

Exclusion criteria

Exclusion Criteria:

  • Inability to complete the intervention program

Absence from more than three consecutive training sessions

Failure to comply with the study protocol

Development of any medical condition during the study period that contraindicates continued participation

04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Active comparator
    Resistance Training

    Eight weeks of progressive resistance training, 3 sessions per week. Each session includes upper body, back, abdominal, and lower body exercises. Training intensity progresses from 60% of 1RM in week 1 to 85% of 1RM in week 8.

    Other: Resistance Training

  • Experimental
    Electrical Muscle Stimulation (EMS)

    Eight weeks of electrical muscle stimulation training, 3 sessions per week. EMS applied to biceps brachii, abdominals, back, and quadriceps muscles using frequency of 35-70 Hz, pulse duration 100 μs, and pulse period 50 ms. Electrode size: 150 × 240 mm. Intensity progressively increased over 8 weeks.

    Device: Electrical Muscle Stimulation

  • Other
    Control

    No exercise intervention during the 8-week study period. Participants are asked to maintain their usual lifestyle and physical activity levels.

    Other: No Intervention

Interventions

  • OtherResistance Training

    Progressive resistance training program including upper body (chest press), back (lat pulldown), abdominal (crunch), and lower body (squat) exercises. Performed 3 times per week for 8 weeks. Each session includes warm-up (10 min), main exercises (30 min), and cool-down (10 min). Intensity: 60-85% of 1RM, progressing weekly.

  • DeviceElectrical Muscle Stimulation

    Electrical muscle stimulation applied to biceps brachii, abdominals, back, and quadriceps muscles using a commercial EMS device. Parameters: frequency 35-70 Hz, pulse duration 100 μs, pulse period 50 ms, electrode size 150 × 240 mm. Performed 3 times per week for 8 weeks, 15 minutes per session. Intensity progressively increased based on participant tolerance.

  • OtherNo Intervention

    Participants in the control group receive no exercise intervention during the 8-week study period.

05

What researchers measure

Primary outcomes

  1. Change in Phase Angle (PhA) as a Cellular Health Index

    Phase angle (PhA) measured using bioelectrical impedance analysis (Inbody770). PhA is calculated as the ratio of reactance (Xc) to resistance (R) and serves as an indicator of cellular health, membrane integrity, and cell function.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week 8).

Secondary outcomes

  1. Change in Serum Superoxide Dismutase (SOD)

    Serum SOD level measured using ELISA kit. SOD is an antioxidant enzyme that catalyzes the dismutation of superoxide radical into oxygen and hydrogen peroxide.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week 8).

  2. Change in Upper Body Strength (Bench Press 1RM)

    Maximum strength of the upper body measured using the bench press 1-repetition maximum (1RM) test.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week 8).

  3. Change in Lower Body Strength (Squat 1RM)

    Maximum strength of the lower body measured using the squat 1-repetition maximum (1RM) test.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week 8).

  4. Change in Upper Body Muscular Endurance (Push-Up Test)

    Upper body muscular endurance assessed using the push-up test. The number of correct push-ups performed within 60 seconds is recorded.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week 8).

  5. Change in Serum Glutathione Peroxidase (GPX)

    Serum GPX level measured using ELISA kit. GPX is a selenium-containing enzyme that catalyzes the reduction of hydroperoxides.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week

  6. Change in Serum Catalase (CAT)

    Serum CAT level measured using ELISA kit. CAT is an enzyme that catalyzes the decomposition of hydrogen peroxide to water and oxygen.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week

  7. Change in Serum Glutathione (GSH)

    Serum glutathione level measured using ELISA kit. GSH is a major intracellular antioxidant that protects cells against oxidative damage.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week

  8. Change in Serum Protein Carbonyl (PC)

    Serum PC level measured using ELISA kit. PC is a marker of protein oxidation and oxidative damage to proteins.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week

  9. Change in Serum Total Antioxidant Capacity (TAC)

    Serum TAC level measured using ELISA kit. TAC reflects the overall capacity of the antioxidant system to neutralize free radicals.

    Time frame: Measured at baseline (before intervention) and 48 hours after the last training session (week

06

Study locations

1 site
  • Faculty of Sport Sciences, University of Birjand
    Birjand, South Khorasan Province 9717434765, Iran
07

References and documents

Individual participant data

Plan to share: No — There is no plan to share individual participant data (IPD) due to ethical and privacy restrictions, as the data contain sensitive personal and physiological information of the participants. Additionally, informed consent was obtained only for the primary study objectives and does not cover secondary data sharing

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07787286
Lead sponsor
Birjand University of Medical Sciences
Responsible party
Mohsen mohammadnia ahmadi (University of Birjand, Birjand University of Medical Sciences) — Principal investigator
First posted
Aug 26, 2026
Start date
Sep 15, 2026 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Mohsen Ahmadi Mohammadnia, Assistant Proffessor
Contact
m.m.ahmadi2005@gmail.com
0985631026917
Mohsen Ahmadi Mohammadnia, Assistant proffesor
Contact
m.m.ahmadi2005@gmail.com
0985631026917
Mohsen Mohammadnia Ahmadi, PhD
principal investigator · university of birjand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion